Multiple Myeloma Pipeline Insight

DelveInsight’s, “Multiple Myeloma (MM) – Pipeline Insights, 2022,” report provides comprehensive insights about 100+ companies and 130+ pipeline drugs in Multiple Myeloma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

Multiple Myeloma Understanding

Multiple Myeloma: Overview

Multiple myeloma is a clonal plasma cell proliferative disorder characterized by the abnormal increase of monoclonal paraprotein leading to evidence of specific end-organ damage. Unchecked, the excess production of these plasma cells can ultimately lead to specific end-organ damage. Most commonly, this is seen when at least one of the following clinical manifestations are present: hypercalcemia, renal dysfunction, anemia, or bone pain accompanied by lytic lesions.


The exact etiology of multiple myeloma is unknown. However, frequent alterations and translocations in the promoter genes, especially chromosome 14, are commonly found in multiple myeloma and likely play a role in disease development. In addition, other oncogenes such as NRAS, KRAS, and BRAF may participate in plasma cell proliferation. Other factors contributing to disease occurrence include obesity, alcohol consumption, environmental causes such as insecticides, organic solvents, agent orange, and radiation exposure.


"Multiple myeloma - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Multiple myeloma pipeline landscape is provided which includes the disease overview and Multiple myeloma treatment guidelines. The assessment part of the report embraces, in depth Multiple myeloma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Multiple myeloma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence R&D Multiple myeloma. The therapies under development are focused on novel approaches to treat/improve Multiple myeloma.
  • MorphoSys and Human Immunology Biosciences, South San Francisco-based biotechnology company focused on discovering and developing precision medicines for autoimmune and inflammatory diseases, announced that the companies entered into an equity participation agreement and license agreements to allow HIBio to develop and commercialize MorphoSys’ felzartamab, an anti-CD38 antibody, and MOR210, an anti-C5aR1 antibody. MorphoSys will receive a 15% equity stake in HIBio and up to $1 billion in milestone payments across programs, plus single- to low double-digit royalties on net sales

Multiple myeloma Emerging Drugs

Elranatamab: Pfizer

Elranatamab is an investigational B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody. Binding affinity to BCMA and CD3 has been optimized, to potentially elicit potent T-cell-mediated anti-myeloma activity. Elranatamab is being investigated as a fixed dose subcutaneous administration, which is intended to allow higher doses than intravenous administration without increasing adverse events. Elranatamab has been granted Orphan Drug Designations by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of MM. The FDA and EMA have also granted elranatamab Fast Track Designation and the PRIME scheme, respectively, for the treatment of patients with MM who are refractory to at least one proteasome inhibitor, one immunomodulatory drug, and one anti-CD38 antibody.


Felzartamab: Janssen Pharmaceutical

Felzartamab (MOR202) is a therapeutic human monoclonal antibody derived from MorphoSys’ HuCAL antibody library and directed against CD38. In Membranous Nephropathy, long-lived plasma cells drive pathogenic antibody production, contributing to functional damage to the glomeruli in the kidney. By targeting CD38, felzartamab has the potential to deplete the CD38 positive plasma cells, which may ultimately improve clinical outcomes in a broad range of autoantibody driven diseases. MorphoSys is currently evaluating the safety and efficacy of investigational felzartamab for patients with anti-PLA2R antibody-positive membranous nephropathy (M-PLACE and NewPLACE trial) and Immunoglobulin A Nephropathy (IGNAZ trial)

Further product details are provided in the report……..

Multiple myeloma: Therapeutic Assessment

This segment of the report provides insights about the Multiple myeloma drugs segregated based on following parameters that define the scope of the report, such as:


Major Players in Multiple myeloma

There are approx. 100+ key companies which are developing the therapies Multiple myeloma. The companies which have their Multiple myeloma drug candidates in the most advanced stage, i.e phase III include Janssen Pharmaceuticals



DelveInsight’s report covers around 130+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of 
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates


Route of Administration

Multiple myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 

  • Oral
  • Intravenous
  • Subcutaneous


Molecule Type

Products have been categorized under various Molecule types such as

  • Small molecule
  • Cell Therapy
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy


Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Multiple Myeloma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I and preclinical stage. It also analyses Multiple Myeloma therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Multiple Myeloma drugs.

Multiple Myeloma Report Insights

  • Multiple Myeloma Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Multiple Myeloma Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Multiple Myeloma drugs?
  • How many Multiple Myeloma drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Multiple Myeloma?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Multiple Myeloma therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Multiple Myeloma and their status?
  • What are the key designations that have been granted to the emerging drugs?


Executive Summary

Multiple myeloma: Overview

  • What is Multiple myeloma?
  • Types of Multiple myeloma
  • Causes
  • Epidemiology and Risk Factors
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Multiple myeloma– DelveInsight’s Analytical Perspective

Late Stage Products (Phase III)

  • Comparative Analysis

Venetoclax: AbbVie

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

PHE885: Novartis

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I/II)

ONC 201: Oncoceutics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

TNB 383B: TeneoBio

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Multiple myeloma Key Companies

Multiple myeloma Key Products

Multiple myeloma- Unmet Needs

Multiple myeloma- Market Drivers and Barriers

Multiple myeloma- Future Perspectives and Conclusion

Multiple myeloma Analyst Views

Multiple myeloma Key Companies


List of Table

Table 1: Total Products for Multiple Myeloma

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Multiple Myeloma

Figure 2: Late Stage Products                              

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products    

• Janssen/Pharmacyclics
• Novartis
• Incyte Corporation
• Gracell Biotechnology
• SpringWorks Therapeutics
• Sana Biotechnology
• Cytovia Therapeutics
• Pfizer
• MorphoSys
• Biokine Therapeutics
• Arcellx
• Rapa Therapeutics
• iTeos Therapeutics
• Sorrento Therapeutics
• CARsgen
• Ascentage Pharma
• Cartesian Therapeutics
• Bristol-Myers Squibb
• Juno Therapeutics
• Nanjing IASO Biotherapeutics
• Arch Oncology
• Oncoceutics
• TeneoBio
• Nerviano Medical Sciences


Forward to Friend

Need A Quote